Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis

A double-blind, placebo-controlled, cross-over trial of nifedipine 10 mg three times daily for 6 weeks, in 10 patients with Raynaud's phenomenon secondary to systemic sclerosis, is reported. A significant reduction in the duration of attacks of Raynaud's phenomenon was observed. Nifedipine...

Full description

Bibliographic Details

Published in:	British journal of dermatology (1951) Vol. 117; no. 2; p. 237
Main Authors:	Meyrick Thomas, R H, Rademaker, M, Grimes, S M, MacKay, A, Kovacs, I B, Cook, E D, Bowcock, S M, Kirby, J D
Format:	Journal Article
Language:	English
Published:	England 01-08-1987
Subjects:	Blood Flow Velocity - drug effects Clinical Trials as Topic Double-Blind Method Humans Nifedipine - therapeutic use Raynaud Disease - drug therapy Raynaud Disease - etiology Scleroderma, Systemic - complications Skin Ulcer - drug therapy Skin Ulcer - etiology
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!